Fresenius SE & Co KGaA (FRE) Stock Rating Reaffirmed by Nord/LB

Nord/LB reiterated their buy rating on shares of Fresenius SE & Co KGaA (FRA:FRE) in a research report report published on Tuesday morning.

Other equities analysts have also issued reports about the company. Morgan Stanley set a €83.00 ($98.81) target price on Fresenius SE & Co KGaA and gave the company a buy rating in a report on Wednesday, October 4th. Citigroup set a €83.00 ($98.81) target price on Fresenius SE & Co KGaA and gave the company a buy rating in a report on Tuesday, October 3rd. Berenberg Bank set a €90.00 ($107.14) target price on Fresenius SE & Co KGaA and gave the company a buy rating in a report on Wednesday, September 20th. Oddo Bhf set a €82.00 ($97.62) target price on Fresenius SE & Co KGaA and gave the company a buy rating in a report on Monday, October 23rd. Finally, Deutsche Bank set a €84.00 ($100.00) target price on Fresenius SE & Co KGaA and gave the company a buy rating in a report on Friday, October 20th. One analyst has rated the stock with a sell rating, five have issued a hold rating and eleven have given a buy rating to the stock. The company currently has a consensus rating of Buy and a consensus price target of €78.66 ($93.65).

Fresenius SE & Co KGaA (FRE) opened at €67.06 ($79.83) on Tuesday. Fresenius SE & Co KGaA has a 1-year low of €60.16 ($71.62) and a 1-year high of €80.00 ($95.24). The firm has a market capitalization of $37,040.00 and a PE ratio of 21.36.

TRADEMARK VIOLATION WARNING: This report was originally reported by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this report on another site, it was stolen and reposted in violation of US and international trademark & copyright law. The legal version of this report can be accessed at https://transcriptdaily.com/2018/01/06/fresenius-se-co-kgaa-fre-stock-rating-reaffirmed-by-nord-lb.html.

Fresenius SE & Co KGaA Company Profile

Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products for patients with chronic kidney failure.

Analyst Recommendations for Fresenius SE & Co KGaA (FRA:FRE)

Receive News & Ratings for Fresenius SE & Co KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co KGaA and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply